Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Prostatic Neoplasms 29Multiple Myeloma 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Lymphoma 20Melanoma 16Lymphoma, Non-Hodgkin 14Colorectal Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Ovarian Neoplasms 13Wilms Tumor 11Myelodysplastic Syndromes 10Lung Neoplasms 10Hodgkin Disease 10Squamous Cell Carcinoma of Head and Neck 9Sarcoma 9Neoplasm Metastasis 9Fallopian Tube Neoplasms 9Carcinoma, Renal Cell 9Burkitt Lymphoma 9Rhabdomyosarcoma 8Rhabdoid Tumor 8Neoplasms 8Leukemia 8Hepatoblastoma 8Glioma 8Colonic Neoplasms 8Sarcoma, Ewing 7Osteosarcoma 7

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Differentiated Thyroid Cancer (DTC) × 30 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡